The IRAK4 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatocellular carcinoma line. This gene-disruption model introduces loss-of-function mutations in IRAK4, enabling study of its role in innate immune signaling in a hepatic epithelial context. The polyclonal format provides a heterogeneous pool of edited alleles for population-level functional analyses, avoiding clonal selection biases and offering a versatile tool for dissecting TLR and IL-1R signal transduction.
The SK-HEP-1 host cell line, established from a liver adenocarcinoma, is a widely used hepatocellular carcinoma model. These epithelial cells retain hepatic metabolic and xenobiotic metabolism functions and are relevant for carcinogenesis studies, exhibiting anchorage-independent growth and tumorigenicity in xenografts. SK-HEP-1 cells are responsive to cytokine and microbial stimuli, making them suitable for knockout models in innate immunity and inflammatory signaling.
IRAK4 is a serine/threonine kinase essential for MyD88-dependent TLR and IL-1R signaling. Upon receptor ligation by IL-1??, IL-18, or TLR agonists, IRAK4 is recruited to MyD88, autophosphorylates, and phosphorylates IRAK1. This triggers TRAF6-mediated K63-linked polyubiquitination, activating TAK1, which phosphorylates the IKK complex (IKK??/IKK??/IKK??) and MAP kinase kinases, leading to NF-??B p65/p50 nuclear translocation and p38/JNK MAPK activation. IRAK4 thus drives transcription of pro-inflammatory cytokines (e.g., IL-6, TNF??) and interacts with regulators like Pellino-1 and Tollip. Disruption of IRAK4 abolishes these responses.
In the SK-HEP-1 liver cancer context, IRAK4 knockout enables dissection of inflammatory pathway contributions to hepatic carcinogenesis. Hepatocellular carcinoma cells exploit IRAK4-dependent signaling for survival, proliferation, and immune evasion; thus, IRAK4 loss allows assessment of TLR/IL-1R impacts on apoptosis resistance, cytokine production, and metastasis. The model retains hepatic metabolic functions, facilitating study of inflammation-driven liver diseases and validation of IRAK4 as a therapeutic target.
Applications include innate immune signaling studies, drug target validation, and inflammatory disease modeling. Typical assays: Western blotting for phospho-IRAK1/IRAK4, RT-qPCR, ELISA for IL-6/TNF??, NF-??B luciferase reporter, flow cytometry for phospho-NF-??B, co-immunoprecipitation of MyD88-IRAK4, and viability/apoptosis assays. The cells can be stimulated with TLR ligands, integrated into sepsis models, or used in cytokine arrays and genome-wide screens. For further technical details, please contact Ascent Research.
